EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
2025 American Association for Cancer Research (AACR) Annual Meeting – Poster Presentations
Title: Preclinical activity and safety of STRO-004, a novel ADC targeting tissue factor for solid tumors Abstract: #1572 Session: PO.ET02.01 - Antibody-Based Cancer Therapeutics 1 Date & Time: Monday, April 28, 2025, 9:00 a.m. - 12:00 p.m. CTPresenter: Alice Yam,...
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - SOUTH SAN FRANCISCO, Calif., April 28, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format...
Society Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer – Presentation
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - SOUTH SAN FRANCISCO, Calif., March 15, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:...
Sutro Biopharma, Inc. Conference Call – Presentation
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel...
15th Annual World ADC London 2025 – Presentation
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 3, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the...
43rd Annual J.P. Morgan Healthcare Conference – Presentation
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., January 7, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...